Ascelia Pharma

Yesterday, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the first quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centered on the status and outlook regarding potential partners and the upcoming potential approval of Orviglance.

Ascelia Pharma is expected to release its Q1 2026 results on 12 May 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event. The Q1 presentation arrives at a pivotal moment for Ascelia Pharma, with the FDA PDUFA decision date for Orviglance set for 3 July 2026 , and ongoing partnership discussions.

Today, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the fourth quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centred on the status and outlook regarding potential partners.

This morning, Ascelia Pharma published its Q4 2025 and full-year results. Beyond the NDA acceptance, the quarter was operationally quiet. Ascelia filed a new patent application. Management reiterates that the runway extends into Q4 2026, and that partner conversations are progressing.